Cargando…
Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2)
Extension of the COVERALL (COrona VaccinE tRiAL pLatform) randomized trial showed noninferiority in antibody response of the third dose of Moderna mRNA-1273 vaccine (95.3% [95% confidence interval {CI}, 91.9%–98.7%]) compared to Pfizer-BioNTech BNT162b2 vaccine (98.1% [95% CI, 95.9%–100.0%]) in indi...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10077822/ https://www.ncbi.nlm.nih.gov/pubmed/37035486 http://dx.doi.org/10.1093/ofid/ofad150 |
| _version_ | 1785020388595466240 |
|---|---|
| author | Griessbach, Alexandra Chammartin, Frédérique Abela, Irene A Amico, Patrizia Stoeckle, Marcel P Eichenberger, Anna L Hasse, Barbara Braun, Dominique L Schuurmans, Macé M Müller, Thomas F Tamm, Michael Audigé, Annette Mueller, Nicolas J Rauch, Andri Günthard, Huldrych F Koller, Michael T Trkola, Alexandra Epp, Selina Amstutz, Alain Schönenberger, Christof M Taji Heravi, Ala Kusejko, Katharina Bucher, Heiner C Briel, Matthias Speich, Benjamin |
| author_facet | Griessbach, Alexandra Chammartin, Frédérique Abela, Irene A Amico, Patrizia Stoeckle, Marcel P Eichenberger, Anna L Hasse, Barbara Braun, Dominique L Schuurmans, Macé M Müller, Thomas F Tamm, Michael Audigé, Annette Mueller, Nicolas J Rauch, Andri Günthard, Huldrych F Koller, Michael T Trkola, Alexandra Epp, Selina Amstutz, Alain Schönenberger, Christof M Taji Heravi, Ala Kusejko, Katharina Bucher, Heiner C Briel, Matthias Speich, Benjamin |
| author_sort | Griessbach, Alexandra |
| collection | PubMed |
| description | Extension of the COVERALL (COrona VaccinE tRiAL pLatform) randomized trial showed noninferiority in antibody response of the third dose of Moderna mRNA-1273 vaccine (95.3% [95% confidence interval {CI}, 91.9%–98.7%]) compared to Pfizer-BioNTech BNT162b2 vaccine (98.1% [95% CI, 95.9%–100.0%]) in individuals with different levels of immunosuppression (difference, −2.8% [95% CI, −6.8% to 1.3%]). |
| format | Online Article Text |
| id | pubmed-10077822 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-100778222023-04-07 Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2) Griessbach, Alexandra Chammartin, Frédérique Abela, Irene A Amico, Patrizia Stoeckle, Marcel P Eichenberger, Anna L Hasse, Barbara Braun, Dominique L Schuurmans, Macé M Müller, Thomas F Tamm, Michael Audigé, Annette Mueller, Nicolas J Rauch, Andri Günthard, Huldrych F Koller, Michael T Trkola, Alexandra Epp, Selina Amstutz, Alain Schönenberger, Christof M Taji Heravi, Ala Kusejko, Katharina Bucher, Heiner C Briel, Matthias Speich, Benjamin Open Forum Infect Dis Brief Report Extension of the COVERALL (COrona VaccinE tRiAL pLatform) randomized trial showed noninferiority in antibody response of the third dose of Moderna mRNA-1273 vaccine (95.3% [95% confidence interval {CI}, 91.9%–98.7%]) compared to Pfizer-BioNTech BNT162b2 vaccine (98.1% [95% CI, 95.9%–100.0%]) in individuals with different levels of immunosuppression (difference, −2.8% [95% CI, −6.8% to 1.3%]). Oxford University Press 2023-03-30 /pmc/articles/PMC10077822/ /pubmed/37035486 http://dx.doi.org/10.1093/ofid/ofad150 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
| spellingShingle | Brief Report Griessbach, Alexandra Chammartin, Frédérique Abela, Irene A Amico, Patrizia Stoeckle, Marcel P Eichenberger, Anna L Hasse, Barbara Braun, Dominique L Schuurmans, Macé M Müller, Thomas F Tamm, Michael Audigé, Annette Mueller, Nicolas J Rauch, Andri Günthard, Huldrych F Koller, Michael T Trkola, Alexandra Epp, Selina Amstutz, Alain Schönenberger, Christof M Taji Heravi, Ala Kusejko, Katharina Bucher, Heiner C Briel, Matthias Speich, Benjamin Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2) |
| title | Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2) |
| title_full | Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2) |
| title_fullStr | Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2) |
| title_full_unstemmed | Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2) |
| title_short | Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2) |
| title_sort | antibody response after third vaccination with mrna-1273 or bnt162b2: extension of a randomized controlled sars-cov-2 noninferiority vaccine trial in patients with different levels of immunosuppression (coverall-2) |
| topic | Brief Report |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10077822/ https://www.ncbi.nlm.nih.gov/pubmed/37035486 http://dx.doi.org/10.1093/ofid/ofad150 |
| work_keys_str_mv | AT griessbachalexandra antibodyresponseafterthirdvaccinationwithmrna1273orbnt162b2extensionofarandomizedcontrolledsarscov2noninferiorityvaccinetrialinpatientswithdifferentlevelsofimmunosuppressioncoverall2 AT chammartinfrederique antibodyresponseafterthirdvaccinationwithmrna1273orbnt162b2extensionofarandomizedcontrolledsarscov2noninferiorityvaccinetrialinpatientswithdifferentlevelsofimmunosuppressioncoverall2 AT abelairenea antibodyresponseafterthirdvaccinationwithmrna1273orbnt162b2extensionofarandomizedcontrolledsarscov2noninferiorityvaccinetrialinpatientswithdifferentlevelsofimmunosuppressioncoverall2 AT amicopatrizia antibodyresponseafterthirdvaccinationwithmrna1273orbnt162b2extensionofarandomizedcontrolledsarscov2noninferiorityvaccinetrialinpatientswithdifferentlevelsofimmunosuppressioncoverall2 AT stoecklemarcelp antibodyresponseafterthirdvaccinationwithmrna1273orbnt162b2extensionofarandomizedcontrolledsarscov2noninferiorityvaccinetrialinpatientswithdifferentlevelsofimmunosuppressioncoverall2 AT eichenbergerannal antibodyresponseafterthirdvaccinationwithmrna1273orbnt162b2extensionofarandomizedcontrolledsarscov2noninferiorityvaccinetrialinpatientswithdifferentlevelsofimmunosuppressioncoverall2 AT hassebarbara antibodyresponseafterthirdvaccinationwithmrna1273orbnt162b2extensionofarandomizedcontrolledsarscov2noninferiorityvaccinetrialinpatientswithdifferentlevelsofimmunosuppressioncoverall2 AT braundominiquel antibodyresponseafterthirdvaccinationwithmrna1273orbnt162b2extensionofarandomizedcontrolledsarscov2noninferiorityvaccinetrialinpatientswithdifferentlevelsofimmunosuppressioncoverall2 AT schuurmansmacem antibodyresponseafterthirdvaccinationwithmrna1273orbnt162b2extensionofarandomizedcontrolledsarscov2noninferiorityvaccinetrialinpatientswithdifferentlevelsofimmunosuppressioncoverall2 AT mullerthomasf antibodyresponseafterthirdvaccinationwithmrna1273orbnt162b2extensionofarandomizedcontrolledsarscov2noninferiorityvaccinetrialinpatientswithdifferentlevelsofimmunosuppressioncoverall2 AT tammmichael antibodyresponseafterthirdvaccinationwithmrna1273orbnt162b2extensionofarandomizedcontrolledsarscov2noninferiorityvaccinetrialinpatientswithdifferentlevelsofimmunosuppressioncoverall2 AT audigeannette antibodyresponseafterthirdvaccinationwithmrna1273orbnt162b2extensionofarandomizedcontrolledsarscov2noninferiorityvaccinetrialinpatientswithdifferentlevelsofimmunosuppressioncoverall2 AT muellernicolasj antibodyresponseafterthirdvaccinationwithmrna1273orbnt162b2extensionofarandomizedcontrolledsarscov2noninferiorityvaccinetrialinpatientswithdifferentlevelsofimmunosuppressioncoverall2 AT rauchandri antibodyresponseafterthirdvaccinationwithmrna1273orbnt162b2extensionofarandomizedcontrolledsarscov2noninferiorityvaccinetrialinpatientswithdifferentlevelsofimmunosuppressioncoverall2 AT gunthardhuldrychf antibodyresponseafterthirdvaccinationwithmrna1273orbnt162b2extensionofarandomizedcontrolledsarscov2noninferiorityvaccinetrialinpatientswithdifferentlevelsofimmunosuppressioncoverall2 AT kollermichaelt antibodyresponseafterthirdvaccinationwithmrna1273orbnt162b2extensionofarandomizedcontrolledsarscov2noninferiorityvaccinetrialinpatientswithdifferentlevelsofimmunosuppressioncoverall2 AT trkolaalexandra antibodyresponseafterthirdvaccinationwithmrna1273orbnt162b2extensionofarandomizedcontrolledsarscov2noninferiorityvaccinetrialinpatientswithdifferentlevelsofimmunosuppressioncoverall2 AT eppselina antibodyresponseafterthirdvaccinationwithmrna1273orbnt162b2extensionofarandomizedcontrolledsarscov2noninferiorityvaccinetrialinpatientswithdifferentlevelsofimmunosuppressioncoverall2 AT amstutzalain antibodyresponseafterthirdvaccinationwithmrna1273orbnt162b2extensionofarandomizedcontrolledsarscov2noninferiorityvaccinetrialinpatientswithdifferentlevelsofimmunosuppressioncoverall2 AT schonenbergerchristofm antibodyresponseafterthirdvaccinationwithmrna1273orbnt162b2extensionofarandomizedcontrolledsarscov2noninferiorityvaccinetrialinpatientswithdifferentlevelsofimmunosuppressioncoverall2 AT tajiheraviala antibodyresponseafterthirdvaccinationwithmrna1273orbnt162b2extensionofarandomizedcontrolledsarscov2noninferiorityvaccinetrialinpatientswithdifferentlevelsofimmunosuppressioncoverall2 AT kusejkokatharina antibodyresponseafterthirdvaccinationwithmrna1273orbnt162b2extensionofarandomizedcontrolledsarscov2noninferiorityvaccinetrialinpatientswithdifferentlevelsofimmunosuppressioncoverall2 AT bucherheinerc antibodyresponseafterthirdvaccinationwithmrna1273orbnt162b2extensionofarandomizedcontrolledsarscov2noninferiorityvaccinetrialinpatientswithdifferentlevelsofimmunosuppressioncoverall2 AT brielmatthias antibodyresponseafterthirdvaccinationwithmrna1273orbnt162b2extensionofarandomizedcontrolledsarscov2noninferiorityvaccinetrialinpatientswithdifferentlevelsofimmunosuppressioncoverall2 AT speichbenjamin antibodyresponseafterthirdvaccinationwithmrna1273orbnt162b2extensionofarandomizedcontrolledsarscov2noninferiorityvaccinetrialinpatientswithdifferentlevelsofimmunosuppressioncoverall2 AT antibodyresponseafterthirdvaccinationwithmrna1273orbnt162b2extensionofarandomizedcontrolledsarscov2noninferiorityvaccinetrialinpatientswithdifferentlevelsofimmunosuppressioncoverall2 |